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Abstract
Background.—Poliovirus (PV) antibody seroprevalence studies assess population immunity, 
verify an immunization program’s performance and vaccine efficacy, and guide polio eradication 
strategy. Namibia experienced a polio outbreak among adults in 2006, yet population 
seroimmunity was unknown.
Methods.—We tested 2061 specimens from Namibian pregnant females aged 15–44 years for 
neutralizing antibody to PV types 1–3 (PV1–3); all females were sampled during the 2010 
National HIV Sentinel Survey. We determined the proportion of females seropositive for PV 
antibody by 5-year age strata, and analyzed factors associated with seropositivity, including age, 
gravidity, human immunodeficiency virus (HIV) infection status, residence, and antiretroviral 
treatment, by log-binomial regression.
Results.—The seroprevalence was 94.6% for PV1, 97.0% for PV2, and 85.1% for PV3. HIV-
positive females had significantly lower seroprevalence than HIV-negative females for PV1 
(91.8% vs 95.3%; P < .01) and PV3 (80.0% vs 86.1%; P < .01) but not for PV2 (96.4% vs 97.1%; 
P = .3). The prevalence ratio of seropositivity for HIV-positive females versus HIV-negative 
females was 0.95 (95% confidence interval [CI], .92–.98) for PV1, 0.99 (95% CI, .97–1.01) for 
PV2, and 0.92 (95% CI, .87–.96) for PV3.
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Conclusions.—Despite relatively high PV seroprevalence, Namibia might remain at risk for a 
PV outbreak, particularly in lower-seroprevalence populations, such as HIV-positive females. 
Namibia should continue to maintain high routine polio vaccination coverage.
Keywords
Poliovirus; polio; seroprevalence; OPV; Namibia; adults; pregnant women; population immunity; 
HIV; neutralizing antibody
Through efforts of the Global Polio Eradication Initiative, indigenous transmission of wild 
poliovirus (WPV) has been interrupted in all countries of the world except Nigeria, 
Afghanistan, and Pakistan. Nonetheless, polio outbreaks following WPV importations have 
been reported in 2013 from a number of countries where polio is not endemic, including 
Cameroon, Ethiopia, Kenya, Somalia, and Syria [1]. Although polio is traditionally a disease 
of childhood, several outbreaks in recent years have affected a larger than expected 
proportion of adults, likely because of immunity gaps, and threaten to spread to other areas 
with an accumulation of polio-susceptible persons [2–4].
Namibia, a country in southern Africa that gained independence from South Africa in 1990, 
had an estimated population of 2.1 million in 2009 and a population density of 2.1 
persons/km2, the second lowest population density in the world [5]. The capital city is Wind-
hoek, and the country is administratively organized into 34 health districts in 14 regions, 
including those with the highest populations, which are located in the northern part of the 
country, along the border with Angola, and those in the central and the southern parts of the 
country [6]. More than 67% of Namibian residents are rural dwellers [7]. In 2012, Namibia 
had one of the highest human immunodeficiency virus (HIV) prevalence rates for adults 
aged 15–49 years in the world, at 13.3% [8], and the overall prevalence was high, compared 
with that in other countries in sub-Saharan Africa [9]. The Expanded Programme on 
Immunization began in 1990 after independence. The current childhood immunization 
schedule includes oral polio vaccine (OPV), given at birth and at 6, 10, and 14 weeks of age, 
with additional OPV doses at 15 months, 5 years, and 10 years of age [10]. Since 2000, 
Namibia implemented ≥2 annual mass OPV campaigns.
In 2006, after 10 years of no reported polio cases, Namibia experienced an outbreak of WPV 
type 1 (WPV1) infection following a WPV1 importation from Angola, with 277 acute 
flaccid paralysis cases reported. Of the reported acute flaccid paralysis cases, 19 were 
laboratory-confirmed polio cases, and 26 were classified as polio-compatible cases [11]. Of 
the 45 reported polio cases, all were among persons ≥14 years of age, and the case-fatality 
ratio was 24%. Reported confirmed polio cases were distributed in the north, along the 
Angolan border, as well as in and around Windhoek [11]. In response to this outbreak, the 
Namibia Ministry of Health and Social Services implemented 3 nationwide supplementary 
immunization activities (SIAs) in 2006, using both house-to-house and fixed-site vaccine 
delivery strategies [11, 12]. The first 2 SIAs targeted adults and children of all ages with 
monovalent OPV type 1, and the third SIA provided trivalent OPV to children <5 years of 
age [12]. Administrative data indicated >95% vaccination coverage in >80% of the 34 
districts [11]. Since the immunization activities associated with the 2006 outbreak response, 
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Namibia has conducted 2 polio national immunization days per year [13]. In 2006, estimated 
routine coverage with 3 doses of OPV among 1-year-old individuals was 74%, increasing to 
84% in 2012 [10].
The 2006 outbreak of WPV1 infection in Namibia exemplified how suboptimal 
immunization coverage can lead to a lapse in population immunity and to a large number of 
accumulated susceptible persons, particularly among older age groups. Although this 
outbreak was followed by multiple OPV rounds in all age groups, likely diminishing the risk 
for another polio outbreak, this outbreak and other recent large-scale outbreaks of WPV 
infection provide evidence that adults may be contributing to sustained poliovirus (PV) 
transmission, highlighting the importance of maintaining strong surveillance and ensuring 
high population immunity across all age groups [2–4,14].
In 2009, the independent Advisory Committee on Poliomyelitis Eradication, which provided 
technical advice to the World Health Organization, recommended conducting PV 
seroprevalence surveys to assess population immunity, verify immunization program 
performance and vaccine efficacy, and guide eradication strategies [15]. Additionally, WPV-
endemic countries and countries at risk of WPV importation were encouraged to develop 
plans for strengthening routine immunization services. Following these recommendations, to 
determine population immunity to PV types 1, 2, and 3 (PV1–3) in Namibia and examine 
factors associated with polio seropositivity, stored serum samples from the 2010 national 
HIV survey were tested. PV antibody seroprevalence estimates provide a tool to (1) assess 
polio immunity in adults following the 2006 outbreak, (2) evaluate response immunization 
activities, and (3) guide the national immunization program’s risk assessment to decrease the 
risk of future polio outbreaks following PV importations.
METHODS
In 2010, the Namibia Ministry of Health and Social Services conducted a nationwide 
sentinel survey to estimate HIV prevalence among pregnant females aged 15–49 years. The 
survey design accorded with the World Health Organization’s standardized methods for HIV 
prevalence surveys, using convenient consecutive sampling of females attending antenatal 
clinics (ANCs) selected on the basis of geographic representation from all regions and health 
districts, urban and rural clinics, areas with different population densities and sizes, and 
females with different socioeconomic status [16, 17]. All pregnant females 15–49 years of 
age were included in the survey if they attended an ANC for the first time during their 
current pregnancy, were not referred from another health facility, and agreed to collection of 
a blood sample for routine syphilis screening.
The 2010 survey enrolled 7983 pregnant females from all 34 districts, which included 35 
main hospitals and 93 satellite health centers and clinics; 7888 of enrollees (98.8%) had 
specimens collected during 22 March-6 September 2010 [17]. Un-linked, de-identified 
specimens were tested for HIV antibodies, de-identified data from all data fields (ie, unique 
identification, district abbreviation and site number, facility type, date of ANC visit, age, 
gravidity, place of residence, antiretroviral therapy participation, and counseling for 
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prevention of maternal-to-child transmission) were retained electronically, and specimens 
were stored at 4–8°C at the Namibia Institute of Pathology in Windhoek.
To estimate PV antibody seroprevalence within each 5-year age group, it was determined 
that 428 specimens per age group were necessary, assuming a seroprevalence of 50%, a 
desired precision of ±5%, a probability of achieving the desired precision of 0.95, and a 10% 
loss due to specimens that were not found or inadequate. We excluded women 45–49 years 
because the number of specimens available in this group was too few to result in meaningful 
estimates. We included all specimens for women 40–44 years because the number available 
was less than the target number. To control the distribution of HIV-infected females within 
each age group, we determined the target sample sizes of the HIV-positive and HIV-negative 
groups by using the observed distribution in the ANC sentinel survey [17].
Samples were tested in triplicate by using a standard microneutralization assay for 
antibodies to PV1–3 according to established protocols at the Global Polio Specialized 
Laboratory, CDC [18,19]. Briefly, 80–100 50% cell culture infectious doses of each PV 
serotype and 2-fold serial dilutions of serum were combined and preincubated at 37°C for 3 
hours before addition of HEp-2(C) cells. After incubation for 5 days at 37°C and 5% CO2, 
plates were stained with crystal violet, and cell viability measured by optical density in a 
spectrophotometer. Each specimen was run in triplicate, with parallel specimens from one 
study subject tested in the same assay run. Neutralization titers were estimated by the 
Spearman-Kärber method [20] and reported as the reciprocal of the calculated 50% end 
point. Each run contained multiple replicates of a reference antiserum pool, starting at a 1:32 
dilution, to monitor performance variation. A serum sample was considered positive if 
antibodies were present at a dilution of ≥1:8. The samples with unobserved titers in starting 
and final dilutions were assigned values of <8 and ≥1448, respectively.
Seroprevalence estimates and 95% confidence intervals (determined by the Wilson-score 
method) were calculated for each age group, as well as within the following subpopulations: 
urban-rural residence, HIV status, antiretroviral therapy status, gravidity, facility type 
(hospital, health center, or clinic), and health district. Health districts with a high HIV 
prevalence were defined as districts with 2010 prevalence of >22% according to sentinel 
survey data. The Cochran-Mantel-Haenszel general association test was used to compare 
seroprevalence among HIV-positive females with that among HIV-negative females, after 
adjustment for age. The ratio of the seroprevalence ( prevalence ratio) among HIV-positive 
females versus HIV-negative females was calculated by log-binomial regression for each 
serotype separately, and each model was examined after controlling for age, urban/rural 
residence, facility type, gravidity, and antiretroviral therapy status, including 2-way 
interaction terms for the aforementioned variables, until the best fitting and most 
parsimonious model for each serotype was determined. Titers were compared using a 
stratified Wilcoxon nonparametric test, with adjustment for age. All analyses included 
sampling weights, which were calculated on the basis of the probability of selection within 
each of the 12 age-HIV infection strata and adjusted for nonresponse (ie, defined as 
specimens that were not available or inadequate for testing). Data were analyzed using SAS, 
version 9.3 (SAS Institute, Cary, NC). This study received ethical approval from the CDC 
and the Namibia Ministry of Health and Social Services.
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RESULTS
On the basis of the sample size calculation, 2692 specimens were selected for inclusion in 
the study; of these, 388 (14%) were not available, 213 (8%) had insufficient volume, and 29 
(1%) were hemolyzed and therefore could not be used for laboratory testing. The remaining 
2062 specimens were shipped to the CDC Global Specialized Poliovirus Laboratory for 
evaluation and testing. Of the 2062 shipped specimens, 2061 were identified by the 
laboratory as suitable for testing for PV1, PV2, and PV3. Of these 2061 specimens, 1 had 
volume sufficient for testing of PV1 and PV3 but not PV2 and was excluded from testing for 
PV2; the remaining 2060 samples had sufficient volume for testing for all 3 PV types. 
Supplementary Table 1 shows the target sample size, the observed sample size, and 
percentage of samples not tested, by age group and HIV status. The analysis comparing 
demographic characteristics of females for whom specimens were not available, insufficient, 
or hemolyzed to the demographic characteristics of females for whom specimens were 
tested and included in analysis found no substantial differences for age group, HIV status, 
urban/rural residence or gravidity (data not shown).
Table 1 shows the overall PV antibody seropositivity for all 3 serotypes. The seroprevalence 
was 94.6% (95% CI, 93.6%– 95.5%) for PV1, 97.0% (95% CI, 96.1%–97.6%) for PV2, and 
85.1% (95% CI, 83.5%–86.6%) for PV3. Seropositivity for any of the 3 serotypes was 
99.1% (95% CI, 98.6%–99.4%). Seropositivity for all 3 serotypes was 80.6% (95% CI, 
78.8%–82.2%). Table 2 shows the PV antibody seroprevalence by age group, urban/rural 
status, gravidity, and facility type; no substantial differences were seen in seroprevalence 
after stratification by these factors. Supplementary Table 2 shows the results for PV antibody 
seroprevalence by health district; seroprevalence varied by health district and ranged from 
77.6% (95% CI, 62.3%– 88.0%) to 100.0% (95% CI, 84.5%–100.0%) for PV1, from 77.0% 
(95% CI, 61.3%–87.6%) to 100.0% (95% CI, 84.5–100.0) for PV2, and from 74.8% (95% 
CI, 56.0%–87.4%) to 94.8% (95% CI, 84.8%–98.4%) for PV3.
Table 3 shows the PV antibody seroprevalence, by HIV status. After controlling for age, 
HIV-positive females had lower PV1 and PV3 seroprevalence than HIV-negative females 
(PV1, 91.8% vs 95.3%; PV3, 80.0% vs 86.1%), and these differences were statistically 
significant (PV1, P =.0015; PV3, P = .0027). HIV-positive females had slightly lower PV2 
seroprevalence than HIV-negative females (PV2, 96.4% vs 97.1%), but this difference was 
not statistically significant (P = .2588).
After controlling for age, the ratio of the prevalence of seropositivity among HIV-positive 
females to that among HIV-negative females was 0.95 (95% CI, .92–.98; P = .0024) for PV1 
and 0.99 (95% CI, .97–1.01, P = .3724) for PV2. After controlling for age, urban/rural 
residence, and gravidity status, the ratio of the prevalence of PV3 seropositivity among HIV-
positive females to that among HIV-negative females was 0.92 (95% CI, .87–.96; P = .0009).
Among females with positive PV antibody titers, the median titer in the HIV-positive group 
was lower than that in the HIV-negative group for PV1 and PV2 but not for PV3 (PV1, 7.2 
vs 8.5 [P<.0001]; PV2, 6.8 vs 7.5 [P<.0001]; PV3, 5.5 vs 5.5 [P = .89]). There were no 
differences in PV antibody seroprevalence for HIV-positive females after stratification by 
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HIV treatment status. No association was found between PV antibody seroprevalence among 
health districts after stratification by high versus low HIV prevalence districts.
DISCUSSION
In 2010, PV antibody seroprevalence among adult pregnant females sampled during the 
ANC sentinel survey in Namibia was >90% for PV1 and PV2 and slightly lower for PV3. 
HIV status affected PV antibody seroprevalence: HIV-positive females had lower PV 
antibody seroprevalence than HIV-negative females for PV1 and PV3 but not for PV2. 
Variation in PV antibody seroprevalence for all 3 types across health districts was observed, 
with the lowest point estimate reaching 74.8% for PV3 in one health district.
This is the first study of adult PV antibody seroprevalence in Namibia. The levels of polio 
population immunity in Namibia could be due to past immunization and/or natural exposure 
to WPV, including during the 2006 outbreak of WPV1 infection. In the past decade, there 
have been a number of PV antibody seroprevalence studies conducted among adult 
populations in Europe that have yielded comparable estimates (seropositivity for PV1, 
73.3%–99.3%; for PV2, 89.9%–99.1%: and for PV3, 70%–98.8%) [21–28]. One exception 
is a study in Uruguay, where seroprotection among adults 20–39 years of age against PV1–3 
ranged from 20% to 60% [29]. Although the herd immunity threshold above which one can 
guarantee the prevention of an outbreak is unknown for African settings such as Namibia, it 
is believed that polio outbreaks in industrialized countries can be prevented with population 
immunity levels of 66%–80% [30]. In developing countries with suboptimal sanitation and 
hygiene leading to the potential for increased PV transmission and greater force of infection, 
WPV outbreaks could theoretically occur with population immunity levels as high as 94%–
97% [30]. Moreover, PV outbreaks including sustained PV transmission among fully 
immunized children have been documented in developing countries [31]. Therefore, until 
polio is eradicated globally, Namibia remains at risk for PV importation, and polio could 
spread among vulnerable populations. To avoid outbreaks following WPV importation and 
to mitigate the spread of a potential outbreak, Namibia should continue to maintain high 
routine polio vaccination coverage and strong acute flaccid paralysis surveillance for rapid 
case detection and response.
These findings should be considered in light of limitations. First, there was no immunization 
history available for participants, so it is unclear whether polio seroimmunity is due to past 
OPV receipt and/or natural immunity, and we could not examine dose-response effects. 
Second, only pregnant females 15–44 years old were examined in this study, and the ANC 
survey was not a random cross-section of the population of pregnant females. Therefore, the 
results may not be generalizable to all pregnant women in Namibia nor other age groups or 
populations. Third, we did not have information on CD4+ T-cell count in the HIV-positive 
females, so we could not examine associations between the level of immunosuppression and 
polio seroprevalence. Fourth, sample sizes were small at the health district level, limiting 
conclusions regarding geographic differences.
The effect of HIV status on seroprevalence for PV1 and PV3 in our study was modest but 
indicated a higher susceptibility to PV infection among HIV-positive females. Past studies 
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that assessed the effect of HIV status on polio immunity are few in number but are in line 
with our results. A study in Italy of HIV-positive and HIV-negative adult drug users found 
lower seropositivity for all 3 PV types in the HIV-positive group [32]. Also, Zimbabwean 
HIV-infected children born to HIV-infected mothers showed significantly lower rates of 
seroconversion to all 3 PV serotypes, compared with HIV-uninfected children, and HIV-
infected children who seroconverted following polio vaccination had lower geometric mean 
titers than HIV-uninfected children [33, 34]. The authors of these studies concluded that the 
association between pediatric HIV infection and poor immunologic response to OPV could 
potentially pose an obstacle to global polio eradication. In studies of HIV infection and viral 
shedding, HIV positivity has not been associated with prolonged viral shedding that could 
potentially lead to the emergence of an immunodeficient vaccine-derived poliovirus [34, 35]. 
Our finding that HIV-positive pregnant females had lower PV1 and PV3 seroprevalences 
than HIV-negative females and that PV seropositive HIV-positive females had lower 
absolute PV1 and PV2 antibody titers than PV seropositive HIV-negative females not only 
could represent higher susceptibility to polio for those females, but also might potentially 
lead to lower polio immunity in their offspring, particularly in HIV-exposed infants who 
become HIV positive.
While WPV2 was eradicated in 1999, the continued use of trivalent OPV, which is known to 
be less immunogenic for PV1 and PV3 than bivalent OPV, in settings with suboptimal PV 
population immunity carries the risk of the emergence of circulating vaccine-derived 
poliovirus type 2 (cVDPV2) and subsequent outbreaks [36]. In light of this, the Strategic 
Advisory Group of Experts Working Group recommended that countries switch from 
trivalent OPV to bivalent OPV in the infant routine immunization schedule [36]. However, 
with this switch, a small risk of the emergence of cVDPV2 exists. Therefore, the Global 
Polio Eradication Initiative Strategic Plan 2013–2018 includes recommendations for 
introducing inactivated polio vaccine in routine immunization services and concurrent use of 
inactivated polio vaccine and bivalent OPV during routine immunization until the time of 
global certification of polio eradication [37]. This strategy will ensure high population 
immunity for all 3 PV types, in Namibia and globally, and will reduce the risk of emergence 
and sustained transmission of vaccine-derived polioviruses.
Conducting periodic seroprevalence surveys in areas at high risk for polio, including polio-
endemic and polio-outbreak countries, and countries considered at risk for PV importation is 
valuable for identifying geographic areas and subpopulations with low polio immunity. 
Results from these surveys can provide some evidence for determining target age groups for 
SIAs, outbreak response, and prioritizing the new recommendations for introduction of 
inactivated polio vaccine and concurrent use of bivalent OPV. Given the high HIV 
prevalence in the African region, further studies in HIV-positive persons and the effect of 
HIV infection on polio seroconversion and seroimmunity might further inform global polio 
eradication strategies.
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Table 1.
Overall and Type-Specific Poliovirus Seroprevalence Among Pregnant Women Aged 15–44 Years, Namibia, 
2010
Poliovirus Type Females, No. (%) 95% CI, %
Positive for type 1 (n = 2061) 1954(94.6) 93.6–95.5
Positive for type 2 (n = 2060) 2000(97.0) 96.1–97.6
Positive for type 3 (n = 2061) 1762(85.1) 83.5–86.6
Positive for any type 2042(99.1) 98.6–99.4
Positive for any type 1671 (80.6) 78.8–82.2
Negative for all types 18 (0.9) .6–1.4
Abbreviation: CI, confidence interval.
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Table 3.
Seroprevalence of Poliovirus Types 1–3 (PV1–3) Among Pregnant Women Aged 15–44 Years, by Human 
Immunodeficiency Virus (HIV) Infection Status and Age Group, Namibia, 2010
HIV Positive (n = 435)
HIV Negative
(n = 1627)
Age in y, by
PV Type
Females,
No. (%)
95%
CI, %
Females,
No. (%)
95%
CI, % P Value
PV1
 Overall 398 (91.8) 88.7–94.2 1556 (95.3) 94.2–96.2 .0015
 15–19 21 (84.0) 64.4–93.8 325 (95.3) 92.5–97.1
 20–24 44 (93.6) 85.7–97.3 299 (92.9) 90.4–94.8
 25–29 76 (92.7) 86.2–96.2 275 (97.2) 95.0–98.4
 30–34 100 (90.9) 83.7–95.1 252 (97.3) 94.3–98.7
 35–39 110 (94.0) 84.9–97.8 242 (94.5) 89.4–97.2
 40–44 47 (87.0) 65.7–95.9 163 (98.8) 91.5–99.8
PV2
 Overall 421 (96.4) 94.0–97.8 1579 (97.1) 96.2–97.8 .2588
 15–19 22 (88.0) 69.1–96.0 330 (97.1) 94.7–98.4
 20–24 45 (95.7) 88.6–98.5 311 (96.6) 94.7–97.8
 25–29 79 (96.3) 91.0–98.6 275 (97.2) 95.0–98.4
 30–34 107 (97.1) 91.9–99.1 254 (98.1) 95.4–99.2
 35–39 115 (98.3) 91.0–99.7 250 (97.7) 93.6–99.2
 40–44 53 (98.2) 80.3–99.9 159 (96.4) 87.8–99.0
PV3
 Overall 353 (80.0) 60.0–91.4 1409 (86.1) 84.4–87.7 .0027
 15–19 20 (80.0) 64.3–95.7 290 (85.0) 80.9–88.5
 20–24 38 (80.9) 70.6–88.1 270 (83.9) 80.5–86.7
 25–29 65 (79.3) 70.8–85.8 252 (89.1) 85.5–91.8
 30–34 90 (81.8) 73.1–88.2 226 (87.3) 82.4–90.9
 35–39 94 (80.3) 68.5–88.5 219 (85.6) 78.8–90.4
 40–44 46 (85.2) 63.5–95.0 152 (92.1) 82.1–96.8
Abbreviation CI, confidence interval.
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